Ozmosi | IBI-301 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

IBI-301

Alternative Names: ibi-301, ibi301, ibi 301
Clinical Status: Inactive
Latest Update: 2026-02-04
Latest Update Note: Clinical Trial Update

Product Description

Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02945215)

Mechanisms of Action: CD20 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innovent
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Diffuse Large B-Cell Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

Phase 2: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Chronic Myeloid Leukemia|Preleukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Biphenotypic Acute Leukemia|Lymphoma, B-Cell|Follicular Lymphoma|Juvenile Myelomonocytic Leukemia,|Myeloid, Accelerated Leukemia|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Acute Monocytic Leukemia|Histiocytosis, Langerhans-Cell|Anemia, Refractory, with Excess of Blasts|Inflammation|Myelodysplastic Syndrome|Lymphocytic Chronic B-Cell Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Hodgkin Lymphoma|B-Cell Leukemia|Myeloproliferative Disorders|Multiple Myeloma|Myelodysplastic-Myeloproliferative Diseases|Leukemia, Plasma Cell

Phase 1: Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Leukemia, Plasma Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Chronic Myelomonocytic Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin|Acute Monocytic Leukemia|Myeloproliferative Disorders|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Myeloid Leukemia|Blast Crisis|Anemia, Aplastic|Biphenotypic Acute Leukemia|Diffuse Large B-Cell Lymphoma|Myeloid, Accelerated Leukemia|Adenocarcinoma|Mycosis Fungoides|Breast Cancer|T-Cell Cutaneous Lymphoma|B-Cell Marginal Zone Lymphoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12622000306718p

2006-7041-83/hah

N/A

Not yet recruiting

Dental Caries|Intestinal Diseases

2022-02-28

NCT05052528

UCDCC#299

P1

Recruiting

Diffuse Large B-Cell Lymphoma

2025-05-15

2024-05-14

NCT02960646

NCI-2016-01915

P1

Completed

Myeloproliferative Disorders|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Anemia, Aplastic|Acute Myeloid Leukemia|Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, Non-Hodgkin|Leukemia, Plasma Cell|Preleukemia|Juvenile Myelomonocytic Leukemia,|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Multiple Myeloma|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Lymphoma, B-Cell|Acute Lymphoid Leukemia

2023-02-13

2023-02-18

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT03432741

MC1689

P1

Terminated

Breast Cancer|Mycosis Fungoides|Adenocarcinoma|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma

2022-08-26

2025-05-28

Primary Completion Date|Primary Endpoints|Treatments

NCT01619761

NCI-2012-02071

P1

Unknown status

Acute Lymphoid Leukemia|Lymphoma, B-Cell|Myeloid, Accelerated Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Biphenotypic Acute Leukemia|Lymphoma, Non-Hodgkin|Preleukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Leukemia, Plasma Cell|Multiple Myeloma

2021-11-01

2022-02-02

Primary Endpoints|Treatments|Trial Status

CTR20160770

CTR20160770

P1

Completed

Lymphoma, B-Cell

2019-10-15

2025-04-29

Patient Enrollment|Treatments

NCT02945215

CIBI301A201

P1

Completed

Lymphoma, B-Cell

2019-03-21

2020-09-03

NCT02779283

IRB00011766

P1

Completed

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia

2018-04-19

2025-02-07

Primary Endpoints|Treatments

CTR20140762

CTR20140762

P1

Completed

Lymphoma, Non-Hodgkin

2016-10-06

2025-04-29

Treatments

NCT02727803

NCI-2016-00584

P2

Recruiting

Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Acute Monocytic Leukemia|Myeloproliferative Disorders|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Anemia, Refractory, with Excess of Blasts|B-Cell Leukemia|Preleukemia|Lymphoma, Non-Hodgkin|Acute Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Chronic Myelomonocytic Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Biphenotypic Acute Leukemia|Myelodysplastic-Myeloproliferative Diseases|Acute Myeloid Leukemia|Multiple Myeloma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell

2027-05-31

2025-05-10

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT06834373

MC230813

P2

Recruiting

Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Inflammation|T-Cell Cutaneous Lymphoma

2027-03-03

2025-04-05

Primary Endpoints|Start Date|Treatments|Trial Status

NCT03096782

NCI-2018-01236

P2

Completed

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Acute Myelomonocytic Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Hodgkin Lymphoma|Myelodysplastic Syndrome|Lymphoma, Non-Hodgkin|Lymphocytic Chronic B-Cell Leukemia|Myeloid, Accelerated Leukemia|Histiocytosis, Langerhans-Cell|Anemia, Refractory, with Excess of Blasts|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Biphenotypic Acute Leukemia|Chronic Myeloid Leukemia|Preleukemia|Chronic Lymphoid Leukemia

2022-09-20

2023-06-30

Primary Endpoints

NCT05457556

ASCT2031

P3

Active, not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Preleukemia

2026-06-30

2025-05-06

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT02003222

NCI-2013-02229

P3

Active, not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2023-06-23

2025-02-07

Primary Endpoints|Treatments

NCT02867566

CIBI301A301

P3

Completed

Diffuse Large B-Cell Lymphoma

2019-09-05

2020-08-14

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date

CTR20160493

CTR20160493

P3

Completed

Diffuse Large B-Cell Lymphoma

2019-09-05

2025-04-29

Patient Enrollment|Treatments